A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus (ELEMENT 5)

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as LY2963016 as compared to LANTUS® in adults with type 2 diabetes mellitus who are on 2 or more oral antihyperglycemic medications (OAMs).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Type 2 Diabetes
What the trial is testing?
LY2963016, Insulin Glargine
Could I receive a Placebo?
No
Enrollment Goal
493
Trial Dates
Dec 1, 2014 - Jul 1, 2016
How long will I be in the trial?
Your participation in this trial could last up to 28 weeks and include 9 visits to the study center.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.